Onfi is a schedule IV (CIV) oral antiepileptic indicated to treat seizures associated with Lennox-Gastaut syndrome (LGS) in adults and children >2 years old. Onfi is thought to potentiate GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor.
The new Onfi scored tablets (10mg and 20mg) will replace the previously available round non-scored tablets, and the 5mg strength will no longer be available. Onfi oral suspension will be available as a 2.5mg/mL strength in a berry flavor.
For more information call (855) 345-6634 or visit Onfi.com.